Optiflow nasal high flow therapy

Proven* respiratory support

                  *A review of studies comprising the body of NHF evidence found the majority used F&P Optiflow™ systems

 

 

While many terms describe NHF, one stands out.
Optiflow NHF therapy. 

Optiflow is at the forefront of its field, featuring in hundreds of publications in journals such as NEJM and JAMA.

Used as a first-line treatment across the care continuum, Optiflow may reduce patient escalation resulting in better clinical outcomes. 

Clinical practice guidelines for NHF therapy


 
Oczkowski et al. Oct. 2021.
European respiratory society (ERS)


This guideline provides recommendations for the following populations:
 
  • Acute hypoxemic respiratory failure
  • Post-operative
  • Post-extubation respiratory failure
  • Rest breaks from NIV
  • Acute hypercapnic respiratory failure


Download the visual abstract

 
Rochwerg et al. Nov. 2020.
European society of intensive care medicine (ESICM)

This guideline provides recommendations for the following populations:
 
  • Acute hypoxemic respiratory failure
  • Post-operative
  • Post-extubation respiratory failure
  • Peri-intubation


Download visual abstract

Optiflow NHF therapy in practice

Optiflow™ Nasal High Flow at the Royal Berkshire Hospital (Optiflow Page)

Optiflow NHF therapy across the care continuum

This video shows the introduction of the Airvo 2 device across departments of the Royal Berkshire Hospital in Reading, UK. Hospital clinicians talk about the benefits found both to the patients and hospital since its introduction.
Extubating to Optiflow™ Nasal High Flow therapy

Extubation to Optiflow NHF therapy:
Dr. Hernández

This video depicts extubation to Optiflow NHF therapy, and is based on the procedure used by Dr. Hernández and his colleagues' in the following studies: Hernández et al. JAMA. 2016 (April)1 and Hernández et al. JAMA 2016 (Oct.)2

ROX Index explained

The ROX index can be used to monitor patients and predict the likelihood of NHF therapy success or failure. 

It combines three common measurements: FiO2, SpO2, and respiratory rate, and it is based on two known facts about sicker patients. 
1.
 They require more oxygen. 
2. They have a higher respiratory rate.

The index has been validated in a multi-center prospective study on 191 patients with pneumonia.*

Read online and download app
Enquire about Optiflow nasal high flow therapy
If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.
Enter security code:*
 Security code
PM-622077_b & DPM-500_a